Mark J. Vignola Sells 9,059 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Mark J. Vignola sold 9,059 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $5.80, for a total value of $52,542.20. Following the sale, the chief financial officer now directly owns 74,752 shares of the company’s stock, valued at $433,561.60. This represents a 10.81 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Terns Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ:TERN traded down $0.04 during midday trading on Monday, reaching $5.71. 1,252,259 shares of the company were exchanged, compared to its average volume of 1,424,849. The stock has a market cap of $485.00 million, a PE ratio of -4.84 and a beta of -0.31. The business’s fifty day moving average is $6.35 and its two-hundred day moving average is $7.41. Terns Pharmaceuticals, Inc. has a one year low of $4.32 and a one year high of $11.40.

Terns Pharmaceuticals (NASDAQ:TERN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.05. As a group, sell-side analysts expect that Terns Pharmaceuticals, Inc. will post -1.19 EPS for the current year.

Institutional Investors Weigh In On Terns Pharmaceuticals

Several large investors have recently bought and sold shares of the business. nVerses Capital LLC bought a new position in Terns Pharmaceuticals during the third quarter valued at $48,000. Sio Capital Management LLC bought a new position in Terns Pharmaceuticals during the 3rd quarter valued at about $83,000. Entropy Technologies LP bought a new position in Terns Pharmaceuticals during the 3rd quarter valued at about $106,000. Bleakley Financial Group LLC raised its position in Terns Pharmaceuticals by 26.0% in the 3rd quarter. Bleakley Financial Group LLC now owns 13,312 shares of the company’s stock worth $111,000 after purchasing an additional 2,751 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Terns Pharmaceuticals by 78.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,535 shares of the company’s stock worth $113,000 after purchasing an additional 5,935 shares during the last quarter. Institutional investors own 98.26% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on TERN shares. BMO Capital Markets reissued an “outperform” rating and issued a $26.00 target price (up from $19.00) on shares of Terns Pharmaceuticals in a report on Monday, September 16th. JMP Securities reissued a “market outperform” rating and issued a $20.00 price objective on shares of Terns Pharmaceuticals in a research note on Wednesday, December 4th. Oppenheimer lifted their target price on shares of Terns Pharmaceuticals from $17.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, December 4th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $7.50 price target on shares of Terns Pharmaceuticals in a research note on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.30.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.